Phathom Pharmaceuticals (PHAT) Finished Goods (2023 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Finished Goods of $1.5 million for Q2 2026, down 38.69% year-over-year from $2.4 million in Q2 2025, and up 0.94% quarter-over-quarter from $1.5 million in Q1 2026.
Phathom Pharmaceuticals (PHAT) Finished Goods (2023 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Finished Goods for 4 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Finished Goods fell 38.69% year-over-year to $1.5 million; the TTM figure through Jun 2026 stood at $1.5 million (down 38.69% YoY), while the FY2025 annual figure was $1.5 million, down 1.49% from the prior year.
- Finished Goods advanced to $1.5 million in Q2 2026 per PHAT's latest filing, from $1.5 million in the prior quarter.
- Across five years, Finished Goods topped out at $2.6 million in Q3 2025 and bottomed at $647000.0 in Q4 2023.
- Historically, Finished Goods has averaged $1.5 million across 4 years, with a median of $1.5 million in 2024.
- Annual changes were most pronounced in 2025 — Finished Goods jumped 177.27% — and 2026, when it plunged 38.69%.
- Phathom Pharmaceuticals' Finished Goods stood at $647000.0 in 2023, then surged by 128.59% to $1.5 million in 2024, then slipped by 1.49% to $1.5 million in 2025, then increased by 2.68% to $1.5 million in 2026.
- Business Quant data shows PHAT's Finished Goods at $1.5 million in Q2 2026, $1.5 million in Q1 2026, and $1.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.50 Mn |
| Mar 31, 2026 | 1.48 Mn |
| Dec 31, 2025 | 1.46 Mn |
| Sep 30, 2025 | 2.60 Mn |
| Jun 30, 2025 | 2.44 Mn |
| Mar 31, 2025 | 1.73 Mn |
| Dec 31, 2024 | 1.48 Mn |
| Sep 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | 880,000.00 |
| Mar 31, 2024 | 818,000.00 |
| Dec 31, 2023 | 647,000.00 |